Venus Medtech's TARGET Study Reveals Effective Cardiovalve TR System for High-Risk Patients

Venus Medtech's TARGET Study Findings



Venus Medtech (Hangzhou) Inc. recently shared significant findings from the TARGET Study during the PCR London Valves 2026. This multicenter, prospective trial focused on the Cardiovalve TR System, aimed at patients with severe tricuspid regurgitation (TR) who are at high risk for traditional surgical procedures.

Study Overview


The TARGET Study enrolled 157 symptomatic patients, with 148 receiving the Cardiovalve TR System. This population had a mean age of 78 years, and a noteworthy 71% were female, all presenting with complex comorbidities. Approximately 40% had torrential TR, significantly complicating their health profiles. The primary endpoints of safety and performance were emphatically met, suggesting a breakthrough for this vulnerable group of patients.

Performance Outcomes


According to the 30-day data, the TARGET Study recorded remarkable results in TR reduction, with data showing that 76.9% of patients achieved none or trace TR at the three-year follow-up. This durable outcome attests to the efficacy of the Cardiovalve TR System and its long-term benefits, which include:

  • - Functional Improvements: Patients demonstrated impressive gains in their physical capabilities, as highlighted by a 42-meter increase in the 6-minute walk test (6MWT) one year post-implant.
  • - Quality of Life Enhancements: The Kansas City Cardiomyopathy Questionnaire (KCCQ) saw an average increase of 20 points at the one-year mark, illustrating better health status among participants.
  • - Improved NYHA Class: Over the study period, there was a significant shift in New York Heart Association (NYHA) class status, with 80% of patients moving to Class I or II by three years compared to 39.9% at the study's inception.

Right Heart Remodeling


Notably, findings indicated favorable right heart remodeling. At the three-year follow-up, significant reductions in the inferior vena cava (IVC) diameter, mid-right ventricular end-diastolic dimension (RVEDD), and basal RVEDD were reported, further endorsing the effectiveness of the treatment.

Safety Measures


Safety data also showed positive results. The primary composite safety endpoint, defined by major adverse events (MAEs), was met as well. All-cause mortality was recorded at 5.7%, with just 1.9% of patients requiring rehospitalization for heart failure and a 5.1% rate for major access site and vascular injuries. Notably, the use of an Enhanced Delivery System led to improved outcomes over the first-generation system, with major bleeding incidents decreasing from 21% to 5.0% and major vascular complications from 8.8% to 3.0%.

Clinical Implications


Professor Georg Nickenig from the Heart Center at the University Hospital Bonn highlighted that these results not only showcase the efficacy of the Cardiovalve TR System but also underline the importance of its favorable safety profile in treating high-risk patients. The advancements pave the way for potential commercialization in the European market, projected for late 2027.

Looking Ahead


As Venus Medtech finalizes its regulatory preparations for CE marking approval, the TARGET Study’s outcomes position the Cardiovalve TR System as a promising treatment option for patients struggling with tricuspid regurgitation. The innovation reflects Venus Medtech's commitment to advancing transcatheter heart valve solutions and improving patient quality of life without the need for invasive surgeries.

With over 150 approved patents, Cardiovalve embodies the forefront of structural heart therapy innovation. As the study unfolds, it stands as a beacon of hope for those suffering from heart-related ailments, emphasizing better health outcomes through cutting-edge medical technology.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.